Clearpoint Competitors

Stocks . USA . 
Stock . Clearpoint Neuro
CLPT Stock  USD 14.52  0.31  2.18%   
Clearpoint Neuro competes with Avita Medical, Sight Sciences, Treace Medical, Neuropace, and Inogen; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Clearpoint Neuro competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Clearpoint Neuro to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Clearpoint Neuro Correlation with its peers.
For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Clearpoint Neuro competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
9.3014.8020.30
Details
Intrinsic
Valuation
LowRealHigh
10.5316.0321.53
Details
Naive
Forecast
LowNextHigh
7.9413.4418.95
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
14.9617.4519.94
Details

Clearpoint Neuro Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Clearpoint Neuro and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Clearpoint and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Clearpoint Neuro does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SRDX
+ 0.9
SGHT
SGHT
+ 0.85
RCEL
APYX
+ 0.83
RCEL
APYX
+ 0.83
SGHT
NPCE
+ 0.82
TMCI
SRDX
+ 0.8
RCEL
  
High negative correlations   
SRDX
- 0.85
TMCI
TMCI
- 0.77
SGHT
NPCE
- 0.74
SGHT
SRDX
- 0.7
NPCE
TMCI
- 0.7
RCEL
NPCE
- 0.68
RCEL

Risk-Adjusted Indicators

There is a big difference between Clearpoint Stock performing well and Clearpoint Neuro Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Clearpoint Neuro's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TBIO  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
RCEL  3.55 (0.36) 0.00 (0.82) 0.00 
 0.00 
 5.14 
(5.03)
 46.29 
SGHT  2.76 (0.61) 0.00 (0.69) 0.00 
 0.00 
 6.25 
(5.80)
 18.90 
TMCI  2.80  0.13  0.04  0.06  2.77 
(3.75)
 8.14 
(4.19)
 20.40 
NPCE  3.01  0.31  0.09  0.25  3.28 
(3.40)
 5.80 
(5.99)
 16.00 
INGN  2.77 (0.22) 0.00 (0.17) 0.00 
 0.00 
 6.01 
(6.56)
 22.98 
SRDX  1.08 (0.30) 0.00 (2.28) 0.00 
 0.00 
 1.67 
(4.06)
 10.84 
LUNG  3.24  0.55  0.19 (0.50) 2.84 
(3.90)
 6.22 
(5.32)
 38.74 
APYX  3.40 (0.34) 0.00 (0.73) 0.00 
 0.00 
 6.02 
(8.65)
 21.55 
OSA  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
All Fundamental Data

Clearpoint Neuro Competitive Analysis

The better you understand Clearpoint Neuro competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Clearpoint Neuro's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Clearpoint Neuro's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CLPT RCEL SGHT TMCI NPCE INGN SRDX LUNG APYX LIVN
 2.18 
 14.52 
Clearpoint
 2.25 
 9.10 
Avita
 0.38 
 2.65 
Sight
 2.08 
 8.94 
Treace
 3.11 
 12.95 
Neuropace
 4.78 
 8.33 
Inogen
 1.26 
 32.86 
SurModics
 6.51 
 8.62 
Pulmonx
 5.07 
 1.45 
Apyx
 1.71 
 41.63 
LivaNova
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Slightly risky
Unstable
Somewhat reliable
Somewhat reliable
Somewhat reliable
Very steady
Slightly risky
Dangerous
Very steady
Market Performance
(90 Days Performance)
Modest
Very Weak
Very Weak
Weak
Modest
Very Weak
Very Weak
OK
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Very High
Average
About Average
High
Low
Low
Quite High
Below Average
Very Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Hold
Hold
Hold
Strong Buy
Hold
Hold
Cautious Hold
Strong Sell
Cautious Hold
Strong Hold
Current Ratio
10.33
9.64
16.73
8.13
9.86
5.32
2.04
9.43
4.45
2.92
Net Asset
39.19 M
79.71 M
166.65 M
217.09 M
107.65 M
326.19 M
178.56 M
162.85 M
79.24 M
428.86 M
Profit Margin
-0.6
-0.96
-0.63
-0.27
-0.37
-0.11
-0.11
-0.67
-0.59
0.0505
EBITDA
(19.75 M)
(55.47 M)
(49.41 M)
(47.27 M)
(22.83 M)
(42.52 M)
1.19 M
(57.7 M)
(18.11 M)
129.1 M
Operating Margin
-0.64
-0.54
-0.56
-0.003
-0.2
-0.14
-0.0061
-0.56
-0.32
0.11
Current Valuation
384.69 M
250.09 M
50.28 M
553.79 M
418.81 M
126.07 M
478.22 M
298.83 M
62.78 M
2.5 B
Price To Book
15.8
53.34
1.41
4.96
40.94
1.27
4.25
4.01
4.71
1.71
Retained Earnings
(191.37 M)
(359.81 M)
(294.79 M)
(189.99 M)
(503.81 M)
(116.95 M)
75.71 M
(467.56 M)
(54.45 M)
(903.25 M)
Current Asset
8.1 M
N/A
N/A
N/A
N/A
114.84 M
58.56 M
N/A
10.01 M
240.72 M
Beta
1.03
1.55
2.51
0.76
2.06
1.03
1.2
0.64
1.25
1.01
Number Of Employees
107
260
214
16
184
20
389
291
252
2.9 K
Shares Outstanding
27.63 M
26.36 M
50.4 M
62.62 M
31.08 M
26.53 M
14.3 M
39.8 M
37.64 M
54.35 M
Cash Flow From Operations
(8.95 M)
(48.94 M)
(47.18 M)
(37.17 M)
(19.7 M)
5.91 M
248 K
(31.54 M)
(5.25 M)
183 M
Total Debt
3.57 M
75.21 M
35.41 M
104.2 M
72.39 M
21.92 M
33.24 M
56.47 M
38.5 M
626.96 M
Return On Equity
-0.68
-2.31
-0.45
-0.44
-2.15
-0.19
-0.12
-0.55
-1.27
0.0487
Return On Asset
-0.28
-0.37
-0.19
-0.15
-0.15
-0.0854
-0.0066
-0.21
-0.22
0.0419
Number Of Shares Shorted
635.68 K
1.94 M
1.41 M
2.26 M
227.95 K
665.89 K
430.86 K
1.15 M
141.85 K
1.94 M
Book Value Per Share
1.05
0.17
1.88
1.81
0.33
7.29
7.82
2.16
0.32
24.29
Current Liabilities
1.85 M
N/A
N/A
N/A
N/A
22.01 M
10.13 M
N/A
2.45 M
31.45 M
Total Asset
39.19 M
79.71 M
166.65 M
217.09 M
107.65 M
326.19 M
178.56 M
162.85 M
79.24 M
428.86 M
Debt To Equity
0.28
0.012
0.18
0.99
1.08
0.07
0.12
0.15
0.017
0.4
Short Ratio
3.17
10.66
6.4
5.15
0.89
2.38
1.3
5.74
7.33
4.31
Target Price
25.0
15.8
4.35
10.91
17.57
10.0
43.0
11.67
3.0
63.4
Shares Owned By Institutions
33.32
24.72
53.31
60.64
64.71
89.18
86.36
93.48
42.05
99.29
Market Capitalization
401.22 M
239.85 M
133.55 M
559.81 M
402.45 M
220.99 M
469.77 M
343.04 M
54.58 M
2.22 B
Price To Earning
-3.36
N/A
N/A
N/A
N/A
61.63
69.21
N/A
4.04
78.67
Price To Earnings To Growth
-0.46
-0.04
N/A
N/A
N/A
3.48
3.9
-0.42
-0.58
0.39
Price To Sales
13.19
3.73
1.68
2.67
5.26
0.66
3.74
4.09
1.12
1.77
Net Income
(18.91 M)
(61.84 M)
(55.55 M)
(55.74 M)
(32.96 M)
(35.89 M)
(11.54 M)
(56.39 M)
(18.85 M)
63.2 M
Earnings Per Share
-0.7
-2.39
-1.01
-0.9
-0.98
-1.52
-1.02
-1.44
-0.82
1.16
Shares Owned By Insiders
7.71
0.77
20.24
26.18
3.87
12.82
3.4
4.94
14.03
0.71
Revenue
31.39 M
64.25 M
81.06 M
209.36 M
65.42 M
335.7 M
126.08 M
83.79 M
52.35 M
1.25 B
Working Capital
23.01 M
36.84 M
150.62 M
126.48 M
76.49 M
134.57 M
60.76 M
111.81 M
57.62 M
735.06 M
Cash And Equivalents
45.14 M
84.17 M
220.1 M
101.53 M
92.41 M
223.62 M
22.09 M
162.09 M
20.06 M
109.02 M
Cash Per Share
1.84
0.67
4.6
1.83
3.72
9.78
1.58
4.35
0.58
2.04
Gross Profit
18.37 M
55.16 M
67.7 M
168.26 M
56.44 M
154.74 M
93.52 M
62 M
29.32 M
872.17 M
Day Typical Price
14.32
8.99
2.62
8.72
12.78
8.28
32.94
8.47
1.39
41.32
Accumulation Distribution
0.0673
0.0395
0.0449
0.093
0.0611
0.0724
0.0419
0.0624
0.13
0.024
Market Facilitation Index
0.99
0.36
0.12
0.84
0.8
0.62
1.41
0.54
0.19
1.0
Daily Balance Of Power
0.3131
0.5556
0.0833
(0.23)
0.4875
0.6129
(0.30)
(1.11)
0.3684
0.7
Period Momentum Indicator
0.31
0.2
0.01
(0.19)
0.39
0.38
(0.42)
(0.60)
0.07
0.7
Rate Of Daily Change
1.02
1.02
1.0
0.98
1.03
1.05
0.99
0.93
1.05
1.02
Day Median Price
14.22
8.94
2.61
8.61
12.7
8.25
32.98
8.39
1.37
41.17
Price Action Indicator
0.46
0.26
0.045
0.23
0.44
0.27
(0.33)
(0.07)
0.12
0.81
Relative Strength Index
50.68
45.81
35.1
51.42
56.15
40.12
46.95
67.32
43.99
31.37
Coefficient Of Variation
1278.24
(1,739)
(606.58)
3779.58
1261.53
(1,564)
(614.51)
910.94
(1,334)
(744.34)
Mean Deviation
3.76
3.55
2.76
2.8
3.01
2.77
1.08
3.24
3.4
1.48
Jensen Alpha
0.4525
(0.36)
(0.61)
0.1313
0.3149
(0.22)
(0.30)
0.5549
(0.34)
(0.34)
Total Risk Alpha
0.5922
(0.18)
(0.51)
0.2185
0.4052
(0.14)
(0.25)
0.7499
(0.21)
(0.27)
Sortino Ratio
0.0988
N/A
N/A
0.0404
0.0872
N/A
N/A
0.1861
N/A
N/A
Downside Variance
20.13
N/A
N/A
8.49
12.7
N/A
N/A
10.55
N/A
N/A
Standard Deviation
5.5
6.33
3.78
3.96
3.76
3.86
1.81
5.39
4.6
2.56
Kurtosis
5.03
19.07
2.04
2.52
(0.18)
2.61
6.63
19.78
0.8972
21.95
Potential Upside
8.38
5.14
6.25
8.14
5.8
6.01
1.67
6.22
6.02
2.15
Treynor Ratio
0.3016
(0.82)
(0.69)
0.0598
0.2454
(0.17)
(2.28)
(0.50)
(0.73)
(0.61)
Maximum Drawdown
39.95
46.29
18.9
20.4
16.0
22.98
10.84
38.74
21.55
20.1
Variance
30.27
40.03
14.27
15.7
14.12
14.93
3.27
29.05
21.14
6.58
Market Risk Adjusted Performance
0.3116
(0.81)
(0.68)
0.0698
0.2554
(0.16)
(2.27)
(0.49)
(0.72)
(0.60)
Risk Adjusted Performance
0.0663
(0.03)
(0.11)
0.0276
0.0664
(0.04)
(0.11)
0.0895
(0.05)
(0.09)
Skewness
0.8246
(2.57)
0.8051
1.34
0.196
(0.71)
(2.19)
3.57
(0.05)
(3.71)
Semi Deviation
4.23
N/A
N/A
2.77
3.28
N/A
N/A
2.84
N/A
N/A
Information Ratio
0.0806
(0.06)
(0.16)
0.0297
0.0827
(0.06)
(0.16)
0.1122
(0.07)
(0.13)
Value At Risk
(5.92)
(5.03)
(5.80)
(4.19)
(5.99)
(6.56)
(4.06)
(5.32)
(8.65)
(2.87)
Expected Short fall
(4.76)
N/A
N/A
(3.75)
(3.40)
N/A
N/A
(3.90)
N/A
N/A
Downside Deviation
4.49
N/A
N/A
2.91
3.56
N/A
N/A
3.25
N/A
N/A
Semi Variance
17.91
N/A
N/A
7.68
10.75
N/A
N/A
8.09
N/A
N/A

Clearpoint Neuro Competition Performance Charts

Five steps to successful analysis of Clearpoint Neuro Competition

Clearpoint Neuro's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Clearpoint Neuro in relation to its competition. Clearpoint Neuro's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Clearpoint Neuro in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Clearpoint Neuro's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Clearpoint Neuro, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Clearpoint Neuro position

In addition to having Clearpoint Neuro in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Banks - Regional Thematic Idea Now

Banks - Regional
Banks - Regional Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Banks - Regional theme has 18 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks - Regional Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Clearpoint Stock Analysis

When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY